Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Inclusion Criteria: * Histologically or cytologically confirmed renal cell cancer * Metastatic disease * More than 75% clear cell histology * Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan * No prior refractory disease, defined as clinical or radiologic progression, during or within 3 months after completion of prior interleukin-2 (IL-2) * Nominally "good" or "intermediate" risk disease, meeting ≥ 4 out of 5 of the following criteria: * Hemoglobin \> 10 g/dL (except for patients with hereditary hemoglobinopathy) * ECOG performance status 0-1 (required) * Calcium normal (corrected) * Patients with hypercalcemia due to malignancy allowed provided it has been controlled for \> 1 month * Primary tumor treated or resected by complete nephrectomy, partial nephrectomy, radiofrequency ablation, or other local ablation * Lactic dehydrogenase \< 1.5 times upper limit of normal (ULN) * No history of or current brain or CNS metastasis by CT scan or MRI within the past 30 days * Performance status - ECOG 0-1 * More than 4 months * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 75,000/mm\^3 * No history of bleeding diathesis * PTT \< 1.5 times ULN * INR \< 1.5 * Bilirubin ≤ 1.5 times ULN * AST and ALT ≤ 2.5 times ULN * No chronic hepatitis B or C * Creatinine ≤ 2.0 mg/dL * No proteinuria\* by dipstick urinalysis * Urine protein ≤ 1,000 mg by 24-hour urine collection * No symptomatic congestive heart failure * No uncontrolled hypertension, defined as systolic blood pressure (BP) \> 160 mm Hg and diastolic BP \> 90 mm Hg * No cardiac arrhythmia * No peripheral vascular disease ≥ grade 2 * No clinically significant peripheral artery disease * None of the following arterial thromboembolic events within the past 6 months: * Transient ischemic attack * Cerebrovascular accident * Unstable angina pectoris * Myocardial infarction * Not pregnant * No nursing during and for 3 months after completion of study treatment * Negative pregnancy test * Fertile patients must use effective contraception before, during, and for 3 months after completion of study treatment * No active infection requiring parenteral antibiotics * No known HIV positivity * No history of allergic reaction to antibody drugs or IL-2 * No psychiatric illness or social situation that would preclude study compliance * No non-healing wound or fracture * No insulin-dependent diabetes * No other uncontrolled illness * No other malignancy requiring active treatment within the past 2 years except nonmelanoma skin cancer * No prior bevacizumab * At least 6 months since prior immunotherapy containing IL-2 * At least 2 months since prior investigational antibodies * More than 4 weeks since prior conventional cytotoxic chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered * No concurrent corticosteroids except replacement corticosteroids for adrenal insufficiency OR inhaled steroids for chronic obstructive pulmonary disease, asthma, or allergic rhinitis * More than 3 weeks since prior radiotherapy and recovered * No prior radiotherapy to the only site of measurable disease unless there has been subsequent disease progression * More than 4 weeks since prior major surgery * At least 24 hours since prior minor surgical procedure, placement of vascular access device, or fine needle aspiration * At least 30 days since prior and no other concurrent investigational agents * More than 10 days since prior anticoagulants * Low-dose anticoagulants for maintenance of vascular access device patency allowed * No concurrent therapeutic warfarin, including warfarin for treatment of deep vein thrombosis or pulmonary embolism * No other concurrent anticancer therapy